ArticleInfectious diseases and therapy2026
Effectiveness, Sex Differences, and Patient Experience in Real-World Use of Long-Acting Cabotegravir and Rilpivirine: Results from a Prospective Study.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong-acting intramuscular cabotegravir plus rilpivirine (LA-CAB/RPV) administered every 2 months (Q2M) has been available in Spain since January 2023 as a switch strategy for HIV treatment. We evaluated characteristics, effectiveness, tolerability, and acceptance, including patient-reported outcomes, stratified by sex in people with HIV switching to LA-CAB/RPV.
methodsObservational, prospective, cohort study in Hospital Clínic of Barcelona, Spain. Participant characteristics according to sex at birth and treatment effectiveness [HIV-RNA < 50 copies/mL by on treatment (OT), modified intention-to-treat (mITT), and intention to-treat (ITT) analyses] were evaluated. Self-administered electronic questionnaires were collected.
resultsFrom February 2023 to February 2025, 57/741 (8%) women and 684/741 (92%) men started LA-CAB/RPV, compared to 816/5901 (14%) women that continued with other antiretroviral therapy (ART) (p < 0.001) in our cohort. Women were older, had longer time since HIV diagnosis and on ART, lower nadir CD4, and were more frequently Spanish-born than men. Effectiveness by OT, mITT, and ITT in the 461 participants (29 women and 432 men) who reached week 52 of follow-up was 96%, 83%, and 83% and 99%, 92%, and 89%, respectively, without significant differences. There were 8 (1.7%) confirmed virological failures and 40 (9%) discontinuations with no significant differences by sex. Acceptance, tolerability of injections, and HIV medication burden globally improved during follow-up. Women reported more medication burden and disclosure worries than men.
conclusionsCompared to our general cohort, proportionally fewer women than men switched to LA-CAB/RPV. Effectiveness, adherence, tolerability, and acceptance were high without significant differences by sex. In this study, women expressed more frequent disclosure issues and showed significantly different baseline characteristics compared to men, highlighting the importance of sex-disaggregated data analysis. These results should be confirmed in larger studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.